KL4-surfactant prevents hyperoxic and LPS-induced lung injury in mice

Pediatric Pulmonology

Volumn 41, Issue 10, 2006, Pages 916-928

  Kinniry, Paul ^a   Pick, Jeremy ^a   Stephens, Scott ^a   Jain, Deepika ^a   Solomides, Charalambos C ^b   Niven, Ralph ^c   Segal, Robert ^c   Christofidou Solomidou, Melpo ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b TEMPLE UNIVERSITY HOSPITAL   (United States)

^c Discovery Laboratories Inc   (United States)

Author keywords

Acute lung injury; Acute respiratory distress syndrome; Mouse model; Neutrophil transmigration; Protein containing synthetic surfactant; Pulmonary inflammation; Surfactant replacement therapy

Indexed keywords

ARTIFICIAL LUNG SURFACTANT; BERACTANT; CD31 ANTIGEN; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; KL4 SURFACTANT; SINAPULTIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; BIOLOGICAL PRODUCT; LIPOPOLYSACCHARIDE; LUNG SURFACTANT; PEPTIDE; SURFACTANT PROTEIN B;

ACUTE LUNG INJURY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL STRUCTURE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIUM CELL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HYPEROXIA; IN VITRO STUDY; LEUKOCYTE COUNT; LEUKOCYTE MIGRATION; LUNG LAVAGE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN CONTENT; ADULT RESPIRATORY DISTRESS SYNDROME; ANIMAL; C57BL MOUSE; DISEASE MODEL; IMMUNOLOGY; INTRANASAL DRUG ADMINISTRATION; LUNG; NEUTROPHIL; PATHOLOGY; PHYSIOLOGY;

ADMINISTRATION, INTRANASAL; ANIMALS; BIOLOGICAL PRODUCTS; BRONCHOALVEOLAR LAVAGE FLUID; DISEASE MODELS, ANIMAL; FEMALE; HYPEROXIA; LIPOPOLYSACCHARIDES; LUNG; MICE; MICE, INBRED C57BL; NEUTROPHILS; PEPTIDES; PULMONARY SURFACTANT-ASSOCIATED PROTEIN B; PULMONARY SURFACTANTS; RESPIRATORY DISTRESS SYNDROME, ADULT; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33749556049     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.20468     Document Type: Article

References (54)

1. Nicholas TE, Doyle IR, Bernsten AD. Surfactant replacement therapy in ARDS: white knight or noise in the system? Thorax 1997;52:195-197.
2. Lewis JF, Veldhuizen R. The role of exogenous surfactant in the treatment of acute lung injury. Annu Rev Physiol 2003;65:613-642.
3. Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, Lamy M, Legall JR, Morris A, Spragg R, Consensus Committee. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994;149:818-824.
4. Donnelly SC, Hasslett C, Reid PT, Grant IS, Wallace WAH, Metz CN, Bruce LJ, Bucala R. Regulatory role for macrophage migration inhibitory factor in acute respiratory distress syndrome. Nat Med 1997;3:320-323.
5. Donnelly TJ, Meade P, Jagels M, Cryer HG, Law MM, Hugli TE, Shoemaker WC, Abraham E. Cytokine, complement, and endotoxin profiles associated with the development of the adult respiratory distress syndrome after severe injury. Crit Care Med 1994;22:768-776.
6. Meduri GU, Kohler G, Headley S, Tolley E, Stentz F, Postlethwaite A. Inflammatory cytokines in the BAL of patients with ARDS: persistent elevation over time predicts poor outcome. Chest 1995;108:1303-1314.
7. Weinberger B, Laskin DL, Heck DE, Laskin JD. Oxygen toxicity in premature infants. Toxicol Appl Pharmacol 2002;181:60-67.
8. Ricard J-D, Dreyfuss D, Saumon G. Ventilator-induced lung injury. Eur Respir J 2003;22:2s-9s.
9. Pison U, Max M, Neuendank A, Weißbach S, Pietschmann S. Host defense capacities of pulmonary surfactant: evidence for 'non-surfactant' functions of the surfactant system. Eur J Clin Invest 1994;24:586-599.
10. Haitsma JJ, Papadakos PJ, Lachmann B. Surfactant therapy for acute lung injury/acute respiratory distress syndrome. Curr Opin Crit Care 2004;10:18-22.
11. Merrill JD, Ballard RA. Pulmonary surfactant for neonatal respiratory disorders. Curr Opin Pediatr 2003;15:149-154.
12. Cochrane CG, Revak SD. Pulmonary surfactant protein B (SP-B): structure-function relationships. Science 1991;254:566-568.
13. Revak SD, Merritt TA, Cochrane CG, Heldt GP, Alberts MS, Anderson DW, Kheiter A. Efficacy of synthetic peptide-containing surfactant in the treatment of respiratory distress syndrome in preterm infant rhesus monkeys. Pediatr Res 1996;39:715-724.
14. Cochrane CG, Revak SD. Surfactant lavage treatment in a model of respiratory distress syndrome. Chest 1999;116:85S-87S.
15. 4-surfactant in preterm infants with respiratory distress syndrome. Am J Respir Crit Care Med 1996;153:404-410.
16. Moya FR, Gadzinowski J, Bancalari E, Saunas V, Kopelman B, Bancalari A, Kornacka MK, Merritt TA, Segal R, Schaber CJ, Tsai H, Massaro J, d'Agostino R, International Surfaxin Collaborative Study Group. A multicenter, randomized, masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants. Pediatrics 2005;115:1018-1029.
17. Sinha SK, Lacaze-Masmonteil T, Valls i Soler A, Wiswell TE, Gadzinowski J, Hajdu J, Berstein G, Sanchez-Luna M, Segal R, Schaber CJ, Massaro J, d'Agostino R, Surfaxin Therapy Against Respiratory Distress Syndrome Collaborative Group. A multicenter, randomized, controlled trial of lucinactant versus poractant alfa among very premature infants at high risk for respiratory distress syndrome. Pediatrics 2005;115:1030-1038.
18. Survanta [package insert]. Columbus, OH: Ross Products Division, Abbott Laboratories Inc; 2004.
19. Notter RH, Wang Z, Egan EA, Holm BA. Component-specific surface and physiological activity in bovine-derived lung surfactants. Chem Phys Lipids 2002;114:21-34.
20. Beers MF, Bates SR, Fisher AB. Differential extraction for the rapid purification of bovine surfactant protein B. Am J Physiol 1992;262:L773-L778.
21. O'Brien CD, Lim P, Sun J, Albelda SM. PECAM-1-dependent neutrophil transmigration is independent of monolayer PECAM-1 signaling or localization. Blood 2003;101:2816-2825.
22. Sweitzer TD, Thomas AP, Wiewrodt R, Nakada MT, Branco F, Muzykantov VR. PECAM-directed immunotargeting of catalase: specific, rapid and transient protection against hydrogen peroxide. Free Radic Biol Med 2003;34:1035-1046.
23. Garlanda C, Parravicini C, Sironi M, De Rossi M, Wainstok de Calmanovici R, Carozzi F, Bussolino F, Colotta F, Mantovani A, Vecchi A. Progressive growth in immunodeficient mice and host cell recruitment by mouse endothelial cells transformed by polyoma middle-sized T antigen: implications for the pathogenesis of opportunistic vascular tumors. Proc Natl Acad Sci USA 1994;91:7291-7295.
24. Christofidou-Solomidou M, Scherpereel A, Solomides CC, Christie JD, Stossel TP, Goelz S, DiNubile MJ. Recombinant plasma gelsolin diminishes the acute inflammatory response to hyperoxia in mice. J Investig Med 2002;50:54-60.
25. Albelda SM, Lau KC, Chien P, Huang Z-Y, Arguiris E, Bohen A, Sun J, Billet JA, Christofidou-Solomidou M, Indik ZK, Schreiber AD. Role for platelet-endothelial cell adhesion molecule-1 in macrophage Fcγ receptor function. Am J Respir Cell Mol Biol 2004;31:246-255.
26. Bradley PP, Priebat DA, Christensen RD, Rothstein G. Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J Invest Dermatol 1982;78: 206-209.
27. Mullane KM, Kraemer R, Smith B. Myeloperoxidase activity as a quantitative assessment of neutrophil infiltration into ischemic myocardium. J Pharmacol Methods 1985;14:157-167.
28. Mizgerd JP, Spieker MR, Doerschuk CM. Early response cytokines and innate immunity: essential roles for TNFR1 and IL1R1 during Escherichia coli pneumonia in mice. J Immunol 2001;166:4042-4048.
29. Fracica PJ, Knapp MJ, Piantadosi CA, Takeda K, Fulkerson WJ, Coleman RE, Wolfe WG, Crapo JD. Responses of baboons to prolonged hyperoxia: physiology and qualitative pathology. J Appl Physiol 1991;71:2352-2362.
30. Minoo P, King RJ, Coalson JJ. Surfactant proteins and lipids are regulated independently during hyperoxia. Am J Physiol 1992; 263:L291-L298.
31. Gross NJ, Smith DM. Impaired surfactant phospholipids metabolism in hyperoxic mouse lungs. J Appl Physiol 1981;51: 1198-1203.
32. Davis JM, Penney DP, Notter RH, Metlay L, Dickerson B, Shapiro DL. Lung injury in the neonatal piglet caused by hyperoxia and mechanical ventilation. J Appl Physiol 1989;67: 1007-1012.
33. Matalon S, Holm BA, Notter RH. Mitigation of pulmonary hyperoxic injury by administration of exogenous surfactant. J Appl Physiol 1987;62:756-761.
34. Loewen GM, Holm BA, Milanowski L, Wild LM, Notter RH, Matalon S. Alveolar hyperoxic injury in rabbits receiving exogenous surfactant. J Appl Physiol 1989;66:1087-1092.
35. Ingenito EP, Mora R, Cullivan M, Marzan Y, Haley K, Mark L, Sonna LA. Decreased surfactant protein-B expression and surfactant dysfunction in a murine model of acute lung injury. Am J Respir Cell Mol Biol 2001;25:35-44.
36. Nogee LM, Garnier G, Dietz HC, Singer L, Murphy AM, deMello DE, Colten HR. A mutation in the surfactant protein B gene responsible for fatal neonatal respiratory disease in multiple kindreds. J Clin Invest 1994;93:1860-1863.
37. Nogee LM, deMello DE, Dehner LP, Colten HR. Deficiency of pulmonary surfactant protein B in congenital alveolar proteinosis. N Engl J Med 1993;328:406-410.
38. Klein JM, Thompson MW, Snyder JM, George TN, Whitsett JA, Bell EF, McCray PB Jr, Nogee LM. Transient surfactant protein B deficiency in a term infant with severe respiratory failure. J Pediatr 1998;132:244-248.
39. Greene KE, Wright JR, Steinberg KP, Ruzinski JT, Caldwell E, Wong WB, Hull W, Whitsett JA, Akino T, Kuroki Y, Nagae H, Hudson LD, Martin TR. Serial changes in surfactant-associated proteins in lung and serum before and after onset of ARDS. Am J Respir Crit Care Med 1999;160:1843-1850.
40. Gregory TJ, Longmore WJ, Moxley MA, Whitsett JA, Reed CR, Fowler AA III, Hudson LD, Maunder RJ, Crim C, Hyers TM. Surfactant chemical composition and biophysical activity in acute respiratory distress syndrome. J Clin Invest 1991;88:1976-1981.
41. Tokieda K, Whitsett JA, Clark JC, Weaver TE, Ikeda K, McConnell KB, Jobe AH, Ikegami M, Iwamoto HS. Pulmonary dysfunction in neonatal SP-B-deficient mice. Am J Physiol 1997; 273:L875-L882.
42. Melton KR, Nesslein LL, Ikegami M, Tichelaar JW, Clark JC, Whitsett JA, Weaver TE. SP-B deficiency causes respiratory failure in adult mice. Am J Physiol Lung Cell Mol Physiol 2003; 285:L543-L549.
43. Suzuki Y, Robertson B, Fujita Y, Grossmann G, Kogishi K, Curstedt T. Lung protein leakage in respiratory failure induced by a hybridoma making monoclonal antibody to the hydrophobic surfactant-associated polypeptide SP-B. Int J Exp Pathol 1992;73: 325-333.
44. Revak SD, Merritt TA, Degryse E, Stefani L, Courtney M, Hallman M, Cohcrane CG. Use of human surfactant low molecular weight apoproteins in the reconstitution of surfactant biologic activity. J Clin Invest 1988;81:826-833.
45. Revak SD, Merritt TA, Hallman M, Heldt G, La Polla RJ, Hoey K, Houghten RA, Cochrane CG. The use of synthetic peptides in the formation of biophysically and biologically active pulmonary surfactants. Pediatr Res 1991;29:460-465.
46. Waring A, Taeusch W, Bruni R, Amirkhanian J, Fan B, Stevens R, Young J. Synthetic amphipathic sequences of surfactant protein-B mimic several physiocochemical and in vivo properties of native pulmonary surfactant proteins. Pept Res 1989;2: 308-313.
47. Epaud R, Ikegami M, Whitsett JA, Jobe AH, Weaver TE, Akinbi HT. Surfactant protein B inhibits endotoxin-induced lung inflammation. Am J Respir Cell Mol Biol 2003;28:373-378.
48. Van Eijk M, De Haas CG, Haagsman HP. Quantitative analysis of pulmonary surfactant proteins B and C. Anal Biochem 1995;232: 231-237.
49. Walther FJ, Hernández-Juviel J, Bruni R, Waring AJ. Protein composition of synthetic surfactant affects gas exchange in surfactant-deficient rats. Pediatr Res 1998;43:666-673.
50. Sood SL, Balaraman V, Finn KC, Britton B, Uyehara CFT, Basa D. Exogenous surfactants in a piglet model of acute respiratory distress syndrome. Am J Respir Crit Care Med 1996;153:820-828.
51. 4-surfactant in models of meconium aspiration syndrome. Pediatr Res 1998;44: 705-715.
52. 4-surfactant) for acute respiratory distress syndrome. Am J Respir Crit Care Med 1999;160:1188-1195.
53. Reiss I, Kuntz S, Schmidt R, Kunz C, Gortner L, Rudloff S. Effect of pulmonary surfactant on TNF-α-activated endothelial cells and neutrophil adhesion in vitro. Immunobiology 2004;209:235-244.
54. Pinot F, Walti H, Haagsman HP, Polla BS, Bachelet M. Curosurf modulates cAMP accumulation in human monocytes through a membrane-controlled mechanism. Am J Physiol Lung Cell Mol Physiol 2000;278:L99-L104.